Authors
Latest:
Future Landscape of BPDCN ManagementDr. Schiller will discuss the limitations of current treatment options for BPDCN in elderly transplant-ineligible patients and the emerging BPDCN research and data that they are most interested in to improve outcomes in this specific patient population.
Latest:
Basu Provides an Overview of MRD GATE RCCArnab Basu, MD, MPH, FACP, discusses molecular residual disease-guided adjuvant therapy in patients with renal cell carcinoma, highlighting the rationale and goals of the MRD gate RCC clinical trial.
Latest:
Unmet Needs and Future Directions for Ovarian CancerThomas C. Krivak MD, John K. Chan, MD, and Cecelia H. Boardman, MD, share insight on recent updates to maintenance therapy, unmet needs, and the future treatment landscape for ovarian cancer.
Latest:
Ongoing Research in Brain Tumor Therapies Provides Hope for the FuturePrimary brain cancers are aggressive, resulting in low survival rates, and pose significant challenges to effective treatment, but ongoing studies signal hope for patients with there tumors.
Latest:
EP. 2B: The Impact of Updated Sub-Analysis Data on the Role of Larotrectinib for NTRK Fusion-positive Thyroid CancerIn the first interview of this series, Steven G. Waguespack, MD, considers long-term safety and efficacy data on larotrectinib and discusses implications for the treatment landscape for NTRK fusion-positive thyroid cancer.
Latest:
Exploring the Design of the ECOG-ACRIN E1411 Trial in MCLMitchell Smith, MD, PhD, discusses the ECOG-ACRIN E1411 trial among patients with previously untreated mantle cell lymphoma.
Latest:
Unpacking the Latest Research in Gastrointestinal CancersIn season 4, episode 1 of Targeted Talks, Benjamin L. Schlechter, MD, discuses new studies in the gastrointestinal cancers space.
Latest:
Treatment Research Landscape in Chronic Lymphocytic LeukemiaJohn Allan, MD, provides insights on novel agents and treatment strategies currently being studied in chronic lymphocytic leukemia.
Latest:
New Pharmacological Frontiers in Neuroendocrine Cancer TreatmentFrom precision radiotherapeutics to small molecule inhibitors, Scott Paulson, MD, discusses a new array of pharmacological treatments for World Neuroendocrine Cancer Day.
Latest:
No-Shave November: The Benefits of the Transperineal Versus Transrectal Approach to Prostate Cancer BiopsyMatthew J. Allaway, DO, discusses the need for a safe, precise and efficient option for performing prostate cancer biopsies via the transperineal approach and the limitations with the current standard of care, which is the transrectal approach, during No-Shave November awareness month.
Latest:
Ribociclib and Endocrine Therapy Improves DFS in Early Breast CancerGabriel Hortabagyi, MD, provides an update on data from the phase 3 NATALEE trial of ribociclib and endocrine therapy in patients with early breast cancer.
Latest:
Exploring Neoadjuvant Treatment in NSCLCBenny Weskler, MBA, MD, FACS, FACCP, discusses the introduction of immune checkpoint inhibitors in the neoadjuvant setting for patients with non–small cell lung cancer.
Latest:
HER2CLIMB-02 Trial to Assess Tucatinib and T-DM1 in HER2+ Breast CancerGiuseppe Curigliano, MD, discussed next steps following the HER2CLIMB study in HER2-positive breast cancer.
Latest:
Novel Therapies in Development for Myelofibrosis Show PromiseSrdan Verstovsek, MD, PhD, highlighted recent advancements in developing novel therapeutic strategies for myelofibrosis during SOHO 2022.
Latest:
Results Demonstrate Accuracy of the 68Ga-PSMA-11 PET for Prostate CancerThomas Hope, MD, discusses the efficacy of the 68Ga-PSMA-11 PET for the detection of pelvic nodal metastases in patients intermediate- to high-risk prostate cancer considered for radical prostatectomy with lymph node dissection.
Latest:
Current and Emerging Developments for the Treatment of Endometrial CancerWesley Burkett, MD, discusses some novel targets that are available and being evaluated in the endometrial cancer space.
Latest:
Stratifying Patients With Pediatric Versus Adult Thyroid CancerAime T. Franco, PhD, discusses how recent research has explored the difference between pediatric thyroid cancer and adult thyroid cancer at the 91st Annual Meeting of the American Thyroid Association.
Latest:
Next Steps for Investigation of Mobocertinib for EGFR Exon 20+ NSCLCDanny Nguyen, MD, discusses next steps for research of mobocertinib in patients with EGFR-positive non–small cell lung cancer.
Latest:
Mechanisms of Resistance to Noncovalent BTK Inhibitors in CLLSkye Montoya, discusses research that she was a part of on mechanisms of resistance to noncovalent Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia.
Latest:
From Paper to Pixel: The Power of Digital Referral SystemsBy expediting referral processes, enhancing information quality, and boosting patient satisfaction, these systems are reshaping healthcare experiences for both providers and patients.
Latest:
AON Creates More Community Oncology Practices Offering Personalized Care in ArizonaShana Wingo, MD, discusses the key goals of the partnership between community oncology practices and American Oncology Network.
Latest:
Investigators Present Updated Results of the OpACIN Trial for MelanomaChristian U. Blank, MD, PhD, discusses the most recent data from the phase 1b OpACIN trial of ipilimumab and nivolumab in patients with macroscopic stage III melanoma.
Latest:
Updated Data From the TRIMM-2 Trial of Talquetamab and Daratumumab in RRMMBhagirathbhai R. Dholaria, MBBS, discusses updated findings from the TRIMM-2 trial of talquetamab and daratumumab for the treatment of relapsed/refractory multiple myeloma.
Latest:
Practical Tips for Diagnosing and Treating BPDCNJames Foran, MD, offers valuable insights on recognizing and treating blastic plasmacytoid dendritic cell neoplasm, emphasizing the importance of early diagnosis, collaboration with specialists, and staying informed about therapeutic advances.
Latest:
Slomovitz on Tisotumab Vedotin's Promise for Cervical CancerBrian Slomovitz, MD, details findings from the innovaTV 301 trial investigating tisotumab vedotin for the treatment of recurrent or metastatic cervical cancer.
Latest:
Can Just-in-Time Clinical Trials Reduce Disparities in Participation?Just-in-time trials are 1 tool capable of rapidly increasing access to clinical trials to develop drugs that treat the diverse and unique tapestry of patients across the United States, especially patients with more diverse racial, ethnic, and socioeconomic backgrounds.
Latest:
Predicting Responses to Immunotherapy in Patients With CancerNatalie I. U. Vokes, MD, discusses the future of predicting how patients will respond to treatment, especially immunotherapy, based on their genomic profile.
